188 related articles for article (PubMed ID: 25403210)
1. Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.
McArthur HL; Morris PG; Hudis CA
J Clin Oncol; 2015 Jan; 33(1):124-5. PubMed ID: 25403210
[No Abstract] [Full Text] [Related]
2. How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.
Reeder-Hayes KE; Carey LA
J Clin Oncol; 2014 Jul; 32(20):2122-4. PubMed ID: 24888811
[No Abstract] [Full Text] [Related]
3. Reply to H.L. McArthur et al.
Vaz-Luis I; Lin NU
J Clin Oncol; 2015 Jan; 33(1):125. PubMed ID: 25403214
[No Abstract] [Full Text] [Related]
4. Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas.
Cabel L; Péron J; Cottu PH; Rodrigues MJ
J Clin Oncol; 2015 Jan; 33(3):291. PubMed ID: 25512462
[No Abstract] [Full Text] [Related]
5. Reply to L. Cabel et al.
Fehrenbacher L; Capra A; Habel L
J Clin Oncol; 2015 Jan; 33(3):292-3. PubMed ID: 25512452
[No Abstract] [Full Text] [Related]
6. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
[TBL] [Abstract][Full Text] [Related]
7. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
8. Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer?
Foekens JA; Martens JW; Sleijfer S
J Clin Oncol; 2015 Mar; 33(7):673-5. PubMed ID: 25605833
[No Abstract] [Full Text] [Related]
9. [HER2-positive breast cancer: standard and double targeted therapy].
Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
Suzuki Y; Ogiya R; Oshitanai R; Terao M; Terada M; Morioka T; Tsuda B; Niikura N; Okamura T; Saito Y; Tokuda Y
Int J Clin Oncol; 2014 Apr; 19(2):274-9. PubMed ID: 23558559
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
12. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Wolff AC; Hammond ME; Hayes DF
J Natl Cancer Inst; 2012 Jun; 104(12):957-8. PubMed ID: 22581974
[No Abstract] [Full Text] [Related]
13. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
Burstein HJ; Winer EP
J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
[No Abstract] [Full Text] [Related]
14. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.
Prat A; Baselga J
J Clin Oncol; 2013 May; 31(14):1703-6. PubMed ID: 23569319
[No Abstract] [Full Text] [Related]
15. Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?
Altundag K
J BUON; 2017; 22(1):281-282. PubMed ID: 28365969
[No Abstract] [Full Text] [Related]
16. Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.
Gavin PG; Song N; Kim SR; Pogue-Geile KL; Paik S
J Clin Oncol; 2015 Nov; 33(31):3671-2. PubMed ID: 26282639
[No Abstract] [Full Text] [Related]
17. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP
N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897
[TBL] [Abstract][Full Text] [Related]
19. Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer.
Lin NU
J Clin Oncol; 2015 May; 33(14):1530-3. PubMed ID: 25847924
[No Abstract] [Full Text] [Related]
20. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
